DataMeds AI's Corexa Pharmacy Unit Completes First Commercial Sale Of One Of Six FDA-Recommended Peptides

 Corexa Pharmacy subsidiary has completed its first commercial sale of one of the six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, together the "Six Peptides") recommended by the U.S. Food and Drug Administration's (FDA) Pharmacy Compounding Advisory Committee (PCAC) at its July 23-24, 2026 meeting, in accordance with U.S. Health and Human Services' (HHS) Enforcement Discretion Policy (EDP). The Six Peptides are compounded drugs, are not FDA-approved and have not been evaluated by FDA for safety or efficacy.

"Corexa Pharmacy has worked through the mechanics of dispensing the Six Peptides in compliance with HHS' recently published Enforcement Discretion Policy," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Now that we have confirmed our ability to dispense the Six Peptides in compliance with recent guidelines in this burgeoning field, we intend to bring our pharmacy hub and distribution warehouse capabilities to the fore to take full advantage of the opportunity. We are currently working through the pricing model and intend to begin actively marketing our offering in a compliant fashion in the very near future. It is crucial to remember that compounded medications are prescribed on a one-to-one basis for individual patients. As such, our marketing will focus on reaching the physicians who prescribe these medications and are able to provide the appropriate oversight, in line with recent guidelines."

The U.S. compounding pharmacy market is expected to grow from $18.02 billion in 2025 to over $31.77 billion by 2034, according to Precedence Research.